In the presence of infection (and its treatment), anticoagulant therapy can go dangerously out of control.
CASE HISTORY
A woman aged 62 attended casualty because the vision in her only eye had suddenly deteriorated after a paroxysm of coughing. She gave a history of aortic and mitral valve replacements for rheumatic heart disease, and was taking warfarin with the aim of keeping the international normalized ratio (INR) between 2.5 and 3.5. A week before presentation she had begun a course of clarithromycin 250 mg twice daily for a chest infection. She had a complex ophthalmic history with bilateral cataract extraction in childhood and bilateral retinal detachment surgery at age 21. The left detachment repair had been successful with restoration of acuity to 6/18, but the right eye had become phthisical (blind and shrunken).
On examination she was pyrexial with signs of a resolving chest infection. There was a left hyphaema in the anterior chamber. The fundus could not be examined because of vitreous opacity. Ocular ultrasonography revealed a dense vitreous and suprachoroidal haemorrhage ( Figure 1 ). Her INR was 8.2. Subsequent examination of the general practitioner's records showed an INR of 2.3 three days before clarithromycin and 2.9 three days into the course. The highest INR in the past four months had been 3.7.
The clarithromycin was stopped, the warfarin dose was adjusted and she was given 0.5 mg intravenous vitamin K. The chest infection cleared three days after admission. A vitrectomy with anterior chamber washout and partial drainage of the suprachoroidal haemorrhage was performed when her INR had fallen to 2.9. Unfortunately this did not improve her vision, which had now deteriorated to perception of light only.
COMMENT
A possible reason for the loss of anticoagulant control in this patient was the infection itself. However, we suspect that the cause was an interaction between clarithromycin and warfarin. This has been recorded in four previous case reports 1±3 . One described the interaction between clarithromycin, warfarin and digoxin in a woman with chronic atrial ®brillation 1 . Her INR at presentation was 7.3. She had gastrointestinal symptoms, weakness, dizziness and visual changes, but no permanent systemic or visual complications ensued. In the other three cases the INR rose to between 5.6 and >20 after taking clarithromycin and warfarin but no systemic symptoms developed 2,3 . Any of these patients could have suffered an intracerebral or other lifethreatening bleed with an elevated INR.
The most common ocular haemorrhagic complication of warfarin is subconjunctival haemorrhage; a rarer one is spontaneous hyphaema. These almost always resolve without Totally implanted venous access systems are widely used in cystic ®brosis and have a low incidence of complications.
Whilst local venous thromboses are described with these devices, we have found no previous reports of permanent superior vena caval occlusion.
CASE HISTORY
A woman with cystic ®brosis (CF) had been colonized with Pseudomonas aeruginosa for many years. She required frequent intravenous antibiotic therapy and because of poor peripheral venous access a Port-a-Cath was inserted into the left subclavian vein in March 1994, when she was 19.
When not in use, the port was¯ushed routinely every four weeks by a trained CF nurse using 5 mL heparin solution (1000 U/mL). During use, the device was¯ushed before and after each access with 5 mL heparinized saline (10 U/mL). In hospital this was done only by designated CF nurses; at home it was done by the patient, after full training.
In September 1995 the patient reported swelling of her arms and face and dilation of the veins on her chest. Superior vena-caval obstruction was diagnosed. Her coagulation pro®le was normal and blood cultures were negative. Angiography revealed thrombus in the superior vena cava (SVC). Streptokinase (25 000 U) was administered via the Port-a-Cath, and she was anticoagulated with heparin and then warfarin to maintain an international normalized ratio of 2±3 times normal. The symptoms of SVC obstruction resolved and the Port-a-Cath remained patent.
In March 1996 the Port-a-Cath became obstructed once again despite adequate anticoagulation and negative blood cultures, and patency could not be restored with urokinase (25 000 U) instilled into the Port-a-Cath line. The device was therefore removed and a new Port-a-Cath was inserted into the right subclavian vein at the same procedure. Thereafter, anticoagulation with warfarin was maintained. However, in October 1996 the replacement Port-a-Cath became occluded, with symptoms of recurrent SVC obstruction. Magnetic resonance scans revealed that the SVC was blocked in its middle third by organizing thrombus (Figure 1 ). Despite repeated streptokinase administration into the Port-a-Cath and adequate anticoagulation with warfarin, the catheter remained unuseable and was removed. In 1998 warfarin therapy was stopped and the patient has been maintained on aspirin ever since. The development of collateral venous drainage temporarily improved peripheral venous access. However, over the subsequent four years it has been increasingly dif®cult to achieve peripheral venous access, and a repeat MRI scan in December 2000 con®rmed the persistence of SVC obstruction preventing the use of upper-body central venous cannulation.
